文献速递白血病

TP53突变及其变异等位基因频率在新诊断成人急性淋巴细胞白血病中的影响

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2026-01-01

该回顾性研究分析新诊断成人急性淋巴细胞白血病(ALL)中TP53突变及其变异等位基因频率(VAF)的预后影响。TP53突变总体发生率17.2%,在≥60岁Ph阴性B细胞ALL且VAF≥45%的患者中4年EFS和OS均为28%,VAF≥45%是独立不良预后因素;年轻患者中TP53状态或VAF不影响生存,但高VAF者复发累积发生率较高。

要点

  • TP53突变在老年及Ph阴性B细胞ALL中更常见。
  • ≥60岁Ph阴性B细胞ALL且VAF≥45%者预后差。
  • 年轻患者中TP53突变或VAF不影响EFS和OS。

核心结论

  • TP53 VAF在老年Ph阴性B细胞ALL中具有预后价值,高VAF增加复发风险;在年轻患者中TP53状态或VAF并非独立预后因素。

研究设计与样本

  • 回顾性分析新诊断成人ALL患者的TP53突变及其VAF。

主要发现

  • TP53突变总体发生率为17.2%,中位年龄61 vs 45岁(P< .001),Ph阴性B细胞ALL中占28% vs 其他3%(P< .001)。
  • 中位TP53 VAF为42%(范围1-94)。
  • ≥60岁Ph阴性B细胞ALL且VAF≥45%者4年EFS和OS均为28%,即使接受前线INO和/或blinatumomab治疗。
  • <60岁接受前线INO和/或blinatumomab者中,TP53突变或VAF不影响EFS或OS;但VAF≥45%者4年累积复发率35%,高于VAF<45%者的8%和野生型无高危特征者的4%。
  • 多因素分析中,≥60岁患者TP53 VAF≥45%与更差结局独立相关;年轻患者中TP53状态或VAF均不能预测结局。

临床怎么用

  • 对老年Ph阴性B细胞ALL患者应检测TP53突变及VAF,VAF≥45%提示高复发风险。
  • 年轻患者TP53 VAF≥45%虽不影响生存,但需关注复发风险升高。

局限性

  • 回顾性研究设计。
  • 缓解时TP53持续存在仅在部分患者中检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53 mutations are associated with unfavorable survival in many hematologic malignancies. However, the impact of TP53 mutations and their variant allele frequency (VAF) in acute lymphoblastic leukemia (ALL) remains unclear. We retrospectively analyzed TP53 mutations and their VAF in newly diagnosed ALL. The overall incidence of TP53 mutations was 17.2%; TP53 mutations were more common in older patients (median age, 61 vs 45 years; P< .001) and in those with Philadelphia chromosome-negative (Ph-) negative B-cell ALL (28% vs 3% in others; P< .001). The median TP53 VAF was 42% (range, 1-94). Patients aged ≥60 years with Ph- B-cell ALL and TP53 VAF ≥45% had poor outcomes, with 4-year event-free survival (EFS) and overall survival (OS) of 28%, driven primarily by increased relapse risk, even among patients treated with frontline inotuzumab ozogamicin (INO) and/or blinatumomab. Among patients aged <60 years who received frontline INO and/or blinatumomab, neither TP53 mutation nor VAF affected EFS or OS. However, younger patients with TP53 VAF ≥45% had higher 4-year cumulative incidence of relapse (35%) than those with VAF <45% (8%) or wild-type TP53 and no high-risk features (4%). In multivariate analysis, TP53 VAF ≥45% was independently associated with worse outcomes in patients aged ≥60 years, but neither TP53 status nor VAF predicted outcomes in younger patients. TP53 persistence at remission occurred in 44% of tested patients and was associated with increased ALL relapse risk. These results demonstrate that TP53 VAF is prognostic in older patients with Ph- B-cell ALL; high VAF may increase relapse risk but is not independently associated with survival in younger patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Azevedo RS, Jabbour E, Kantarjian HM, et al. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. Blood. 2026. PMID: 41335402. doi:10.1182/blood.2025030498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。